pharma consultant

View All

COMMON COLD
Potential cure for Common cold

A group of Researchers at Imperial College London created a molecule that can successfully block multiple strains of the common cold by targeting a protein required for the survival of the virus. The newly created molecule (IMP-1088) resides inside a protein in cells called N-myristoyltransferase (NMT). After invadi...

Find More

Natural Killer Cell Therapies: An Emerging Cellular Therapy

Natural killer cells are the innate immune cells that are naturally involved in tumor immunosurveillance. These cells have direct cytotoxic activity and also secrete proinflammatory cytokines upon activation. Natural killer cells’ cytolytic activity is dependent on a balance between inhibitory signals and activating...

Find More

Familial Amyloid Polyneuropathy – An uncommon medical condition

Familial Amyloid Polyneuropathy (also known as transthyretin amyloidosis, TTR, and FAP) is a group of endangering multisystem disorders which are transmitted as an autosomal dominant trait. It is caused by the excessive accumulation of amyloid in the organs and tissues. The first identified cause of FAP is the Val30...

Find More

Hereditary Angioedema (HAE) – Active drug pipeline

Hereditary Angioedema (HAE) is an autosomal dominant disease which is caused by a deficiency in functional C1 inhibitor. It is a rare hereditary disease which is characterized by painful, unpredictable, recurrent attacks of inflammation and swelling affecting the hands, feet, face, abdomen, urogenital tract, and the...

Find More

transthyretin amyloidosis
NOTIZIA

British scientists looking forward to treat Alzheimer’s disease through diabetes drug A group of British scientists are looking for the treatment of Alzheimer’s disease in an unlikely source i.e. a drug used for treating Type 2 Diabetes. The team, from Lancaster University, has reported that an experimental three-p...

Find More

transthyretin amyloidosis
Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln’s anti-malarial drug

Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (HPV) targeting drug for testing. The new drug is competing to become the sixth PD-1/PD-L1 drug on the market. Joined with...

Find More

transthyretin amyloidosis
Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allergan on women’s health

Positive Phase 2 data for Roche’s lymphoma ADC Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab has already received breakthrough designation from the USFDA and priority medicine status in the EU, and the expectations for the same are running pretty high. Phase 2 data presented by the company at...

Find More

Toll-Like Receptor Modulators: Emerging therapy for many indications

Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals. These receptors were first discovered in Drosophila melanogaster in the late 20th century which later led to the identification of mammalian homologs. Human TLR family consists of...

Find More

Delveinsight
Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires

Novartis ventures itself into developing new editing technology Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&D work in the arena of cell and gene therapy. The deal involves Novartis using the gene editing technology ...

Find More